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The resumption of pituitary and ovarian activity was
investigated by hormonal measurements and ultrasound
scanning in 45 healthy post-partum women who were treated
with bromocriptine. Bromocriptine, 50 mg (Parlodel LAR)
was administered within 24 h post-partum. Plasma luteinizing
hormone, follicle stimulating hormone, oestradiol, pro-
gesterone and prolactin concentrations were measured
repeatedly and correlated with ultrasound measurements.
Forty-one of the 45 women completed the study. A prompt
fall in prolactin levels to normal (non-pregnant) values was
observed within 24 h post-partum. Hereafter, a rapid return
of the normal menstrual cycle was observed. Endocrine
evidence of ovulation was obtained in 19/41 women within
1 month post-partum. Ultrasound measurements started at
day 10 and were repeated regularly in 40 women. Ultrasound
evidence of ovulation was found in 25/40 women. Ultrasound
findings appeared not to correspond with the hormonal
measurements. It is concluded that the resumption of pituitary
and ovarian secretory functions post-partum is not always
paralleled by a concomitant recovery of normal foUicular
growth and ovulation. Application of a progesterone threshold
to judge resumption of ovulation post-partum should be
reconsidered.
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Introduction
In Europe, for many years now, 2-bromo-a-ergocriptine has been
the single most important drug for the suppression of puerperal
lactation. Bromocriptine has been shown to reduce increased
puerperal prolactin levels to the normal non-pregnant range within
24-48 h after the beginning of treatment (Valsamis et al., 1987;
Kremer et al., 1990a). It blocks the initiation of lactation and
prevents breast engorgement and mastodynia. No rebound
lactation occurs, particularly not when a depot form of bromo-
criptine is applied [Parlodel LA (long-acting) or Parlodel LAR
(long-acting repeatable)] (Rolland et al., 1986; Kremer et al.,
1990b). Bromocriptine allows a rapid return of pituitary activity
post-partum. This is reflected in a rapid resumption of ovarian
activity as judged by endocrine parameters. Hormonal signs of
ovulation may occur as early as 21 days post-partum (Kremer
et al., 1990a).
Several investigators have compared ultrasound findings with
hormonal parameters in the normal menstrual cycle (Hackeloer
et al., 1979; Wetzels et al., 1982; Bryce et al., 1982). The aim
of the present investigation was to study, during puerperal
suppression of lactation, the resumption of pituitary and ovarian
function by means of ultrasound and hormonal parameters. This
is the first study to combine hormonal and ultrasound measure-
ments in post-partum research. We wanted to determine whether
the rapid return of ovarian endocrine activity is accompanied by
normal follicle development and ovulation, as judged by
ultrasound.
Suppression of lactation was obtained by i.m. administration
of 50 mg Parlodel LAR. Parlodel LAR consists of microspheres
of glucose-initiated poly D,L-lactide-coglycolide containing
bromocriptine. The suspension of the microspheres in a vehicle
containing carboxymethyl cellulose is made prior to the injection.
Materials and methods
Patients
Forty-five women participated in the study. The following
inclusion criteria were selected, (i) No wish to breastfeed,
(ii) Willingness to remain hospitalized for at least 1 day after
the Parlodel LAR injection and to return to the hospital or be
available at home for blood-sampling and ultrasound examina-
tions on selected days thereafter, (iii) No relevant abnormal
findings at the initial physical examination prior to drug
administration, nor any abnormal laboratory value regarding vital
functions.
No concomitant treatment that could influence the patients'
metabolic or hormonal state was given during the observation
period. Informed consent was given verbally in the presence of
a third person. The protocol of the study was approved by the
ethical committee of our hospital.
Seventeen women were primiparous, 28 were multiparous;
mean age was 28 years (range 17 — 35 years); mean height
166 cm (range 155-178 cm); mean weight 75 kg (range
57-109 kg). All subjects had regular menstrual cycles prior to
the present pregnancy. In seven women, the pregnancy was
complicated by hypertension, three women received insulin
therapy because of gestational diabetes and one woman had a
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placental abruption at 38 weeks. Forty-four women delivered at
term, one woman delivered prematurely at 29 weeks. Three
women delivered by Caesarean section.
Intervention
A deep intragluteal injection of bromocriptine, 50 mg (Parlodel
LAR) was administered within 24 h after delivery, at 0800 h.
Hormonal measurements
To study the post-partum resumption of gonadotrophic function,
blood samples were taken prior to the bromocriptine administra-
tion and 1 ,2 ,3 ,4 ,6 , 12 and 24 h following the administration.
Further blood samples were taken on days 2, 4, 7, 10, 14, 17,
21, 28, 42 and 60, at home, always between 0800 and 1000 h.
The serum was separated and frozen until assayed. All samples
from each subject were measured in the same assay run.
Prolactin, oestradiol-17-/3, luteinizing hormone (LH) and follicle
stimulating hormone (FSH) levels were measured.
Serum hormone concentrations were measured in duplicate.
All between-assay coefficients of variations were < 8%. Serum
LH and FSH levels were determined by luminescence assay with
Amerlite LH-30 and FSH-60 clone kits (Amersham, UK). The
results are expressed in terms of International Reference
Preparation (IRP) 68/40 for LH and K P 79/549 for FSH. The
detection limit for LH was 0.12 U/l and for FSH 0.5 U/l. Serum
oestradiol and progesterone were measured by radioimmunoassay
(Coat-a-count, Diagnostic Products, Los Angeles, CA). The
detection limit for oestradiol was 0.03 nmol/1 and for progesterone
0.45 nmol/1. Serum prolactin levels were determined by
Pharmacia Delfia Prolactin assay with reference to IRP 84/500
and with a detection limit of 0.001 U/l.
Progesterone levels were measured on days 14, 17, 21 and
28. At first, concentrations ^ 6 nmol/1 were used as indicators
of an ovulatory cycle, as suggested by Kremer and co-workers
(1990b). This threshold value was chosen to allow comparison
with data in the literature. Cycles with a mid-luteal progesterone
level <9.6 nmol/1 (3 ng/ml) have been considered to reflect a
lack of luteinization (Israel et al., 1972). In addition, in cycles
with serum progesterone <32 nmol/1, Radwanska and Swyer
(1974) found an incidence of ovulation disturbances as high as
50%, but at levels > 32 nmol/1, the incidence was only 4%. For
that reason, we regrouped our results in two other ways according
to the highest progesterone value: > 9.6 nmol/1 and > 32 nmol/1.
Ultrasound evaluation
Follicular growth and ovulation were monitored by ultrasound
at regular intervals. A real time scanner was used (Pie Medical
Scanner 150, Maastricht, The Netherlands). Ultrasound examina-
tions started on day 10 and were repeated on days 14, 17, 21,
24 and 28 or until ovulation had occurred. If an ovulation was
expected between two measurements, scans were done more
frequently until ovulation was established. All ultrasound
measurements were performed at home. Due to the position of
the ovaries 2 weeks post-partum, only abdominal scans were
made. Ovulation was characterized by steady growth of a follicle,
followed by complete disappearance of the sonolucent area or
by a sharp reduction in its size.
As additional signs of ovulation, the appearance of free fluid
in the pouch of Douglas and filling-in of the follicular content
with echodense structures were used. In case a follicle did not
rupture, ultrasound scans were continued until the largest follicle
had reached a diameter of 30 mm, or until the follicle did not
grow any further for two successive measurements. All follicles
were scanned in three perpendicular directions, and the mean
diameter was calculated (Hamilton, 1986).
Statistical analyses
For statistical analyses Wilcoxon's test for non-parametric data
was used. The pre-assigned significance level was P < 0.05.
The results are expressed as means ± standard deviations.
Results
Forty-five women entered the study and 41 women completed
it as scheduled. Following the Parlodel LAR injection, four
women withdrew, each for personal reasons. After leaving the
hospital, three women declined further blood sampling and
ultrasound examinations. One woman was withdrawn due to
technical problems with blood sampling.
Prolactin
As expected, all women had high plasma prolactin concentra-
tions following delivery and prior to injection of Parlodel LAR
(3.22 ± 1.70 U/l). Within 12 h after the administration of
Parlodel LAR, all women showed a rapid fall in plasma prolactin
levels to 0.33 ± 0.20 U/l (normal non-pregnant range
0.10—0.60 U/l) (Figure 1). Seven women showed a minor
increase of prolactin levels on day 10, 17 or 21 with a maximum
of 1.15 U/l. Only two women showed slight signs of engorge-
ment, without pain or milkflow. In three women with a minor
increase of prolactin, ultrasound examination did reveal signs of
ovulation.
LH and FSH
FSH and LH levels were below the level of detection (LH < 0.1
U/l; FSH <0.5 U/l) for the first 2 days after delivery. FSH first
prolactin
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Fig. 1. Serum prolactin levels in 41 women after the administration
of 50 mg depot-bromocriptine on day 1 post-partum.
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became detectable by day 7 in 29 women. All women had a rise
in FSH levels by day 10. Following the initial increase, maximum
levels were observed on day 14 (6.7 ± 2.23 U/l). Thereafter,
the FSH levels declined slowly, comparable with a normal
ovulatory cycle.
LH first became detectable on day 7 in 13 women and was
detectable in 34 women by day 10. LH started to rise later than
FSH and increased more slowly. Maximum levels were reached
on day 21 (6.73 ± 5.92 U/l) (Figure 2).
Oestradiol-17P
Within 7 days, all women reached early pre-ovulatory oestradiol
levels (normal range: early follicular phase 0.2—1.5 nmol/1
during ovulation 1.3—2.2 nmol/1, luteal phase 0.7-1.5 nmol/1).
A nadir was seen on day 10 (0.45 ± 0.19 nmol/1) followed by
LH and FSH
U/L
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Fig. 2. Serum luteinizing hormone (LH) and follicle stimulating
hormone (FSH) levels in 41 post-partum women after the
administration of 50 mg depot-bromocriptine on day 1 post-partum.
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a significant increase with a maximum on day 21 of 0.95 ± 0.50
nmol/1 (Figure 3).
Progesterone
High levels of progesterone were measured at the time of the
administration of Parlodel LAR: 63.0 ± 46.6 nmol/1 (normal
range early follicular phase 0.3-2.0 nmol/1). Early follicular
levels were measured in all women on days 14, 17 and 21.
Increased levels were obtained on day 28. In 19 women, a
progesterone level 5:6 nmol/1 was obtained, 16 women had a
level >9.6 nmol/1 and only four women would have had an
ovulatory cycle had 32 nmol/1 been used as the threshold for
ovulation. The mean levels of progesterone on day 28 were
11.3 nmol/1 (range 0.1-67.4 nmol/1) (Figure 4).
Ultrasound evaluation
Valid ultrasound measurements were obtained in 40 of the 41
patients. In 35%, transonic areas indicating follicle growth were
seen at the first scan on day 10. Ultrasound findings appeared
not to correspond with the hormonal findings.
In Table I different threshold levels of progestrone are shown,
as related to the ultrasound findings. If a threshold of 6 nmol/1
was used as an indication of an ovulatory cycle, 19 women would
have had an ovulation. In 12 of these women, ultrasound
progesterone
nmol/1
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Fig. 4. Serum progesterone levels of 41 post-partum women after
the administration of 50 mg depot-bromocriptine on day 1 post-
partum.
Table I. Hormonal measurements compared with ultrasound findings in
post-partum non-lactating women treated with bromocnpUne
Progesterone
threshold
(nmol/1)
Ultrasound (no. of patients)
Ovulation No ovulation
Fig. 3. Serum oestradiol levels in 41 post-partum women after the
administration of 50 mg depot-bromocriptine on day 1 post-partum.
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measurements corresponded with the hormonal parameters. In
five women the ultrasound scans were inconclusive: follicle
growth was seen without evidence of ovulation, and the follicle
disappeared slowly or became cystic without evidence of rupture.
In one woman, no follicle growth could be observed, and in one
woman no scans were made. In 22 women, progesterone levels
< 6 nmol/1 were obtained. Surprisingly, 13 of these 22 women
had evidence of ovulation on ultrasound scanning. In six women,
only follicle growth but no ovulation was observed and three
women showed no follicle growth at all. If the threshold was
raised to 9.6 or 32 nmol/1, an increasing difference between
ultrasound and hormonal measurements would have been
observed. Sixteen women had progesterone levels >9.6 nmol/1,
only four women had levels >32 nmol/1. Of the 16 women with
a progesterone >9.6 nmol/1, only 11 showed ovulation on ultra-
sound scanning. In one woman, ultrasound revealed no follicle
growth at all. Progesterone levels in her case reached a maximum
of 10.9 nmol/1. Twenty-five women had a progesterone level
< 9.6 nmol/1 on day 28. In this group, 14 women had ultrasound
signs of ovulation, in nine women only follicle growth could be
observed without an ovulation and two had no follicle growth
at all.
In all women with a progesterone ^ 32 nmol/1, ovulation was
affirmed by ultrasound. In the 37 women who had progesterone
levels <32 nmol/1 21 had an ovulation on ultrasound. Thirteen
women showed follicle growth only and only two had no follicle
growth at all (in one woman, no ultrasound measurements were
made). If ovulation was seen on ultrasound examination, it always
occurred between day 17 and day 28.
Using the ultrasound examinations as a reference, the hormonal
data were rearranged. In 25 of the 40 women an ovulation was
diagnosed by ultrasound. In this group, 12 women had
progesterone :S6 nmol/1, 13 women > 6 nmol/1, 11 women
^9.6 nmol/1 and only four women had progesterone levels
>32 nmol/1.
In all women with no evidence of follicle growth on ultrasound
examination, the ovaries were easy to identify. In the 37 women
who showed evidence of follicle growth or ovulation on
ultrasound scanning, 32 had a concomitant rise in oestradiol. In
all women with at least a doubling of oestradiol, ultrasound
confirmed ovulation.
Discussion
The resumption of gonadotrophic function in post-partum non-
lactating women treated with bromocriptine (Parlodel LAR) in
our study is in accordance with results from the literature. A
prompt fall in prolactin to normal non-pregnant levels was seen
within 24 h post-partum. This initiated a return of the normal
menstrual cycle starting with the rise of FSH levels between day
7 and day 10, followed by an increase in LH levels. Progesterone
levels suggesting ovulation (;>6 nmol/1) were observed in 19
women on day 28. This threshold value was used to allow
comparison with data in the literature. In our opinion, this
threshold is however too low to ascertain that ovulation has taken
place. For that reason, we used three different threshold levels:
progesterone S 6 nmol/1, ^9.6 nmol/1 and ^32 nmol/1.
Although serum progesterone samples were only taken on day
21 and 28 in the first month post-partum, we strongly believe
that these findings are conclusive with regard to luteal activity,
because they were highly correlated with an oestradiol rise in
the follicular phase. All women with a rise of oestradiol in the
follicular phase showed a rise in progesterone levels at day 28
and no significant changes in oestradiol levels occurred in women
with low progesterone levels at day 28.
Our data indicate that, based on hormonal findings, a quick
return of pituitary and ovarian function would be expected, with
an ovulation in almost 50% of the women within 4 weeks post-
partum. Ultrasound measurements in our study, however,
revealed that in the first month post-partum, many subtle
disturbances occur in follicle growth and ovulation. Therefore,
hormonal parameters suggesting ovulation do not always reflect
a complete return to normal prepregnant ovarian function.
Accuracy in comparison with ultrasound findings was 47.5%
if a progesterone threshold of 6 nmol/1 was applied, 57.5% at
9.6 nmol/1 and 47.5% at 32 nmol/1. The increased occurrence
of anovulatory cycles and defective luteal phases in the
puerperium and following a spontaneous abortion has been
described before (Gray et al., 1987; Donnet et al., 1990). The
return to normal in the subsequent cycles suggests a gradual
recovery of hypothalamic or pituitary function after childbirth.
In the early puerperium, the reproductive axis remains
dormant, presumably in part because of pituitary refractoriness
to gonadotrophin releasing hormone (GnRH) stimulation, in part
because of ovarian refractoriness to gonadotrophin stimulation
(Vemer, 1979). In the course of the first few spontaneous
menstrual cycles, normal ovarian ovulation activity is gradually
restored.
The present study draws attention to the dissociation between
the endocrine activity of pituitary and ovary and functional
ovarian activity, i.e. follicle growth and ovulation. The biological
activity of a given glycopeptide hormone is not always accurately
reflected in even the most highly specific radioimmunological
assay. Moreover, gonadotrophins are secreted in multiple
heterogeneous forms. The specific biological activity of FSH
isohormones may influence follicular development post-partum
profoundly without the overall immunoactivity being a suitable
indicator. Deglycosylated glycoproteins have, for example, been
shown to be competitors of the intact hormone in receptor
binding, but these isohormones have decreased potencies to
stimulate steroidogenesis (Calvo et al., 1986). The ratio between
bioactive and immunoactive FSH varies throughout the menstrual
cycle and throughout reproductive life (Jia et al., 1986). It is
tempting to speculate that the lack of association between ovarian
secretory and ovulatory activity in the early post-partum period
reflects in part the dissociation between the several active
components of the reproductive system, which our routine
laboratory immunoassays were unable to pick up.
The importance of differential stimulation of the ovary by the
two most important pituitary glycoprotein hormones has recently
been demonstrated by Mannaerts and co-workers (1991). They
showed, in rats, that administration of pure (recombinant) FSH
induced antral follicle growth, but no steroidogenesis. After the
combined administration of FSH and LH the plasma oestradiol
levels increased in an FSH dose-dependent manner. The
differentia] increase of puerperal FSH and LH levels found in
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the present study might be responsible for the dissociation
between steroidogenesis and foUiculogenesis in the first menstrual
cycle post-partum.
In conclusion, our findings demonstrate that even if hormonal
changes suggest ovulation, the first spontaneous cycle after
delivery is often characterized by disturbances of follicle growth
and follicle rupture. Further research in this area is needed to
find explanations for this difference between the hormonal and
ultrasonic findings.
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